OPTIMISING SYNCHROTRON MICROBEAM RADIATION THERAPY FOR CANCER TREATMENT

Grant number: 606614 | Funding period: 2010 - 2012

Completed

Abstract

Over 50% of cancer patients receive radiotherapy (RT). Tumour control using RT is limited by adverse normal tissue reactions. Unlike conventional RT machines, the Australian synchrotron has the capability to deliver strong radiation in very thin slices, termed microbeam RT (MRT). Tumour control has been obtained in animal models with a remarkable sparing of normal tissue using MRT. We will optimize MRT as a crucial step towards a potentially revolutionary cancer treatment.

Related publications (5)

University of Melbourne Researchers